Key Developments: St. Jude Medical Inc (STJ)

STJ on New York Consolidated

65.68USD
28 Aug 2014
Price Change (% chg)

$0.81 (+1.25%)
Prev Close
$64.87
Open
--
Day's High
--
Day's Low
--
Volume
700,159
Avg. Vol
1,535,134
52-wk High
$71.90
52-wk Low
$49.94

Search Stocks

Latest Key Developments (Source: Significant Developments)

St. Jude Medical Inc completes acquisition of NeuroTherm
Thursday, 7 Aug 2014 08:00am EDT 

St. Jude Medical Inc:Completes acquisition of privately held NeuroTherm, Inc., amanufacturer of interventional pain management therapies.  Full Article

St. Jude Medical Inc announces third quarter dividend
Tuesday, 29 Jul 2014 06:16pm EDT 

St. Jude Medical Inc:Declares third quarter dividend of $0.27 per common share.This dividend amount is equal to dividend paid during first and second quarters of 2014 and brings total dividend declared for year to $0.81 per share.Payable Oct. 31, 2014, to shareholders of record on Sept. 30, 2014.  Full Article

St. Jude Medical Inc announces CE Mark approval and first use of FlexAbility Ablation Catheter
Tuesday, 22 Jul 2014 08:00am EDT 

St. Jude Medical Inc:Says CE Mark approval and first use of FlexAbility Ablation Catheter, novel ablation technology used by electrophysiologists for the treatment of cardiac arrhythmias.Designed with feedback from physician thought-leaders around world, FlexAbility catheter combines a unique, irrigated flexible catheter tip with a state-of-the-art handle and catheter design.Next-generation flexible tip technology was designed to reduce complications associated with ablation procedures through ability to bend and conform to cardiac anatomy, decreasing amount of pressure distributed to patient's heart wall while simultaneously increasing the stability of therapy delivery.European approval of FlexAbility ablation catheter further strengthens St. Jude Medical's fast-growing ablation technology portfolio.  Full Article

St. Jude Medical Inc gives Q3 2014 outlook below analysts' estimates; raises FY 2014 EPS outlook; raises low end of prior FY 2014 revenue outlook to a range in line with analysts' estimates
Wednesday, 16 Jul 2014 07:30am EDT 

St. Jude Medical Inc:Expects Q3 2014 revenue to be in the range of $1.315 -$1.395 bln.Expects Q3 2014 adjusted net earnings to be in the range of $0.95 to $0.97 per share.Expects FY 2014 revenue to be in the range of $5.640 -$5.760 bln.Expects FY 2014 adjusted net earnings to be in the range of $3.96 to $4.01.Q3 2014 revenue of $1.439 bln, EPS of $1.00 - Thomson Reuters I/B/E/S.FY 2014 revenue of $5.702 bln, EPS of $3.99 - Thomson Reuters I/B/E/S.  Full Article

St. Jude Medical Inc announces definitive agreement to acquire NeuroTherm
Monday, 14 Jul 2014 09:00am EDT 

St. Jude Medical Inc:SignS definitive agreement to acquire privately held NeuroTherm, Inc., manufacturer of interventional pain management therapies.Says for about $200 mln in cash.  Full Article

St. Jude Medical Inc completes acquisition of CardioMEMS
Monday, 2 Jun 2014 08:56am EDT 

St. Jude Medical Inc:Completed its acquisition of privately held CardioMEMS Inc, developer of the CardioMEMS HF System.The acquisition was completed on May 30.  Full Article

St. Jude Medical Inc and CardioMEMS announces FDA approval of CardioMEMS heart failure management system
Wednesday, 28 May 2014 12:38pm EDT 

St. Jude Medical Inc and CardioMEMS:U.S. Food and Drug Administration (FDA) approval of CardioMEMS HF System.CardioMEMS HF System is first and only FDA-approved heart failure (HF) monitoring device that has been proven to significantly reduce HF hospital admissions when used by physicians to manage heart failure.CardioMEMS HF System uses a miniaturized, wireless monitoring sensor that is implanted in the pulmonary artery.  Full Article

St. Jude Medical announces TOCCASTAR clinical trial meets primary safety and efficacy endpoints at heart rhythm 2014
Wednesday, 7 May 2014 05:44pm EDT 

St. Jude Medical Inc:Announced results of the TOCCASTAR clinical trial at Heart Rhythm 2014, the Heart Rhythm Society's 35 Annual Scientific Sessions in San Francisco.Results from the first prospective, randomized study of contact-force ablation technology for the treatment of paroxysmal atrial fibrillation met primary endpoints and supplement the growing body of evidence that supports the safety and effectiveness of contact-force ablation technology.Says TOCCASTAR study is a multicenter, non-inferiority study evaluating 300 patients in the U.S. and Europe.  Full Article

St. Jude Medical Inc declares second quarter dividend
Wednesday, 30 Apr 2014 07:00pm EDT 

St. Jude Medical Inc:Declares second quarter dividend of $0.27 per common share.That brings the total dividend declared for the year to $0.54 per share.The dividend is payable July 31.Payable to shareholders of record on June 30.  Full Article

St. Jude Medical Inc gives Q2 2014 outlook in line with analysts' estimates; lowers FY 2014 outlook
Wednesday, 16 Apr 2014 07:30am EDT 

St. Jude Medical Inc:Expects Q2 2014 revenue to be in the range of $1.380 to $1.460 billion.Q2 2014 consolidated adjusted net earnings to be in the range of $0.99 to $1.01 per share.Expects FY 2014 total revenue to be in the range of $5.610 to $5.760 billion.FY 2014 consolidated adjusted net earnings to be in the range of $3.95 to $4.00.Q2 2014 revenue of $1.441 bln and EPS of $1.00 - Thomson Reuters I/B/E/S.FY 2014 revenue of $5.694 bln and EPS of $3.98 - Thomson Reuters I/B/E/S.  Full Article

Fitch Affirms St. Jude Medical's at 'A'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, August 20 (Fitch) Fitch Ratings has affirmed St. Jude Medical, Inc.'s (STJ) Issuer Default Rating (IDR) at 'A' with a Stable Rating Outlook. Fitch has also affirmed the company's short-term IDR at 'F1'. A full list of Fitch's rating actions is available at the end of this release. The ratings apply to approximately $4.21 billion of debt outstanding as of June 28, 2014. KEY RATING DRIVERS Fitch's rating actions reflect the f

Search Stocks